Basel, Basel-Stadt, Switzerland 11-50 Corporate Venture Capital, Venture Capital Early Stage Venture, Late Stage Venture, Post-Ipo, Secondary Market, Seed www.nvfund.com 8,369
Industries FinanceTherapeuticsVenture CapitalHeadquarters Regions Europe, Middle East, and Africa (EMEA) Sub-Organization of NovartisFounded Date 1996 Founders Argeris Karabelas Operating Status Active Also Known As Novartis Bioventure Fund Related Hubs Novartis Venture Fund Portfolio Companies
Investor Type Corporate Venture Capital, Venture Capital Investment Stage Early Stage Venture, Late Stage Venture, Post-Ipo, Secondary Market, Seed Number of Exits
Company Type For Profit
Contact Email klydon@sosei.com Phone Number 877 280 2296
Novartis Venture Fund's primary focus is on the development of novel therapeutics and platforms. They balance the therapeutic focus with investments in medical devices, diagnostics, or drug delivery systems. In their investments, they look for unmet needs and clinical impact, novel proprietary science, an understanding of mechanism, management
and board experience, and capital efficiency in the program.
Novartis Venture Fund prefers to have their initial investment at the early stage to build the company and follow with additional investment in pace with the company's progress. Their approach involves larger focused investments, with anticipation of total investments up to USD 30 to 50 million per company over its life, but it can be as little as 100,000 USD to get started. They plan to increase their activities to lead or co-lead deals further and remain open to participating in larger syndicates.